Peptron, Inc. (KOSDAQ: 087010)

Market Cap	2.14T
Revenue (ttm)	2.50B
Net Income (ttm)	-19.62B
Shares Out	20.66M
EPS (ttm)	-954.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,023,669
Open	126,500
Previous Close	125,700
Day's Range	112,500 - 131,200
52-Week Range	21,100 - 132,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 087010

Financial Performance

In 2023, Peptron's revenue was 3.34 billion, a decrease of -42.52% compared to the previous year's 5.81 billion. Losses were -15.92 billion, 5.70% more than in 2022.